The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review
Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with trea...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2011/374213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561891925295104 |
|---|---|
| author | Carlos E. Araya Vikas R. Dharnidharka |
| author_facet | Carlos E. Araya Vikas R. Dharnidharka |
| author_sort | Carlos E. Araya |
| collection | DOAJ |
| description | Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with treatment response. We found 18 reports of 39 transplant recipients who received rituximab. By univariate analysis for two outcomes (no response versus any response), fewer rituximab infusions and normal serum albumin at recurrence were associated with treatment response. For 3 outcomes (no response, partial and complete remission), male gender, fewer rituximab infusions, shorter time to rituximab treatment, and normal serum albumin were associated with remission. Multivariate analysis for both models revealed that normal serum albumin at FSGS recurrence and lower age at transplant were associated with response.
Rituximab for recurrence of FSGS may be beneficial for only some patients. A younger age at transplant and normal serum albumin level at recurrence diagnosis may predict response. |
| format | Article |
| id | doaj-art-12cad67d39044603adef42b4db6091a6 |
| institution | Kabale University |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-12cad67d39044603adef42b4db6091a62025-02-03T01:23:51ZengWileyJournal of Transplantation2090-00072090-00152011-01-01201110.1155/2011/374213374213The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic ReviewCarlos E. Araya0Vikas R. Dharnidharka1Division of Pediatric Nephrology, University of Florida College of Medicine, 1600 SW Archer Road, Room HD-214, Gainesville, FL 32610-0296, USADivision of Pediatric Nephrology, University of Florida College of Medicine, 1600 SW Archer Road, Room HD-214, Gainesville, FL 32610-0296, USARecurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with treatment response. We found 18 reports of 39 transplant recipients who received rituximab. By univariate analysis for two outcomes (no response versus any response), fewer rituximab infusions and normal serum albumin at recurrence were associated with treatment response. For 3 outcomes (no response, partial and complete remission), male gender, fewer rituximab infusions, shorter time to rituximab treatment, and normal serum albumin were associated with remission. Multivariate analysis for both models revealed that normal serum albumin at FSGS recurrence and lower age at transplant were associated with response. Rituximab for recurrence of FSGS may be beneficial for only some patients. A younger age at transplant and normal serum albumin level at recurrence diagnosis may predict response.http://dx.doi.org/10.1155/2011/374213 |
| spellingShingle | Carlos E. Araya Vikas R. Dharnidharka The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review Journal of Transplantation |
| title | The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review |
| title_full | The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review |
| title_fullStr | The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review |
| title_full_unstemmed | The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review |
| title_short | The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review |
| title_sort | factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis a systematic review |
| url | http://dx.doi.org/10.1155/2011/374213 |
| work_keys_str_mv | AT carlosearaya thefactorsthatmaypredictresponsetorituximabtherapyinrecurrentfocalsegmentalglomerulosclerosisasystematicreview AT vikasrdharnidharka thefactorsthatmaypredictresponsetorituximabtherapyinrecurrentfocalsegmentalglomerulosclerosisasystematicreview AT carlosearaya factorsthatmaypredictresponsetorituximabtherapyinrecurrentfocalsegmentalglomerulosclerosisasystematicreview AT vikasrdharnidharka factorsthatmaypredictresponsetorituximabtherapyinrecurrentfocalsegmentalglomerulosclerosisasystematicreview |